Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

COUCH Medcomms

- PMLiVE

Empowering Nurses Through Education

Nurse education is powerful and makes an impact.

Medscape Education Global

- PMLiVE

Johnson & Johnson to expand dermatology portfolio with $850m Proteologix acquisition

The company will gain access to two treatments for atopic dermatitis

- PMLiVE

GSK becomes first founding partner of global initiative tackling antimicrobial resistance

AMR could cause an estimated ten million deaths every year by 2050 unless action is taken

- PMLiVE

Governments continue proposed pandemic agreement progress ahead of World Health Assembly

The meeting focusing on ‘All for Health, Health for All’ takes place on 27 May to 7 June 2024

- PMLiVE

Study reveals new breast cancer genes found in women of African ancestry

More than 240,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

The PM Society announces Sumira Riaz as Patient Engagement Interest Group co-chair

Riaz has been working as a patient engagement lead at OPEN Health for the last seven years

Enhancing Virtual Training: Role-Playing in Meetings – Impetus InSite Tips #7

Explore the effectiveness of role-playing in virtual meetings with our seventh tip. Learn how assigning roles like "influencer" or "educator" can deepen understanding and enhance communication skills among participants.

Impetus Digital

- PMLiVE

Bristol Myers Squibb’s Breyanzi granted FDA accelerated approval for follicular lymphoma

The disease accounts for up to 30% of all non-Hodgkin lymphoma cases

- PMLiVE

Takeda’s Qdenga becomes second dengue vaccine to receive WHO prequalification

Approximately half of the global population is at risk of mosquito-borne viral disease

- PMLiVE

AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

- PMLiVE

UCB shares positive phase 3 results for Zilbrysq in generalised myasthenia gravis

Zilbrysq is the first C5 inhibitor to show a clinically meaningful reduction of fatigue in the rare autoimmune disease

- PMLiVE

Exploring medical education and why it relies on real-world research

Onyx Health's Head of Medical Education, Sarah Seilly, explains our approach to MedEd and the benefits of tailoring your own

Onyx Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links